Here's What to Watch in European Stocks This Morning
(Bloomberg) -- Good morning. Here's what we are watching ahead of the market open in Europe:
Turkey's Priorities
Turkey didn't stay out of the spotlight for long. The government reignited fears that it's prioritizing growth over controlling its surging inflation, after announcing a wide range of new tax cuts. The lira slumped and the nation's bonds dropped. Separately, note that the latest comments from Istanbul on the manner of columnist Jamal Khashoggi's death are likely to keep tensions between the Turkey and Saudi Arabia elevated. The European stocks most exposed to Turkey could fall at the open, such as Spanish lender BBVA, which was counting the cost of the crisis on Tuesday. Swedish telecoms operator Telia Co. and carmakers like France's Renault SA are also exposed.
Cable's Climbing
Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials' announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21. The latest jump in the currency followed a report from The Times of London saying an agreement had been struck to maintain U.K. banks' access to EU markets and data post-Brexit. A stronger currency is potentially bad news for a whole raft of dollar earners in the FTSE 100 benchmark this morning, although investors will also contemplate the benefits that a more straightforward divorce could have on British firms' international trading capabilities. Note that today is also Bank of England rate-decision day.
READ: BOE Rate-Hike Plans Hamstrung by Brexit: Decision Day Guide
Disaster Tabs
When disaster strikes, insurers invariably foot the bill. The non-life sector endured a torrid October, with Zurich-based sector heavyweight Swiss Re and the U.K.'s Lancashire Holdings Ltd and RSA Insurance Group Plc all releasing profit warnings blamed largely on the natural catastrophes and extreme weather conditions seen across the globe in the spring and summer months. Last night, U.S. provider American International Group Inc. slipped in after-hours trading after natural disasters weighed on its third quarter, although another update from Swiss Re noted that sector may have now turned a corner for the year. Lancashire also gives another update before the open, and its outlook will be eyed by the entire sector.
Tariff Winner
The world's largest steel producer, Dutch-listed ArcelorMittal reported “significantly improved” earnings for the first nine months of the year. The firm is continuing to benefit from U.S. President Donald Trump's tariffs, which have slashed cheaper imports of the metal from countries like China. “Market conditions remain favorable,” it said. The report could be a marker for the entire metals sector this morning, while investors in close peers like Stockholm-traded SSAB AB will have a particular interest.
READ: Stocks in Asia Attempt November Rally; Pound Jumps: Markets Wrap
Big Health Day
Health care earnings just won't stop coming. At midday in London, investors in Japan's Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they're asked to vote on a $62 billion bid to buy the Dublin-headquartered firm. Prior to that, two other London-listed firms -- medical-device producer Smith & Nephew Plc and opioid addiction treatment-maker Indivior Plc -- also update. Elsewhere, the world's largest maker of insulin, Denmark's Novo Nordisk A/S and ostomy-care firm Coloplast A/S, also update.
To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net
To contact the editors responsible for this story: Beth Mellor at bmellor@bloomberg.net, Tom Lavell
©2018 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.